<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546130</url>
  </required_header>
  <id_info>
    <org_study_id>RNCLC-01</org_study_id>
    <nct_id>NCT00546130</nct_id>
  </id_info>
  <brief_title>Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer</brief_title>
  <acronym>RNCLC</acronym>
  <official_title>Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toyama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Toyama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether setting test groups of cisplatin + irinotecan
      + Krestin therapy as first-line treatment and chemotherapy (radiotherapy or radiotherapy +
      chemotherapy also allowed) combined with Krestin as second-line treatment after exacerbation
      and comparing with historical control or community control is appropriate as the protocol and
      regimen for the phase III clinical trial on extensive-stage disease (ED) small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine whether the following protocol and regimen is appropriate for the phase III
      clinical trial on extensive-stage disease (ED) small cell lung cancer: set test groups of
      cisplatin + irinotecan + Krestin therapy as first-line treatment and chemotherapy
      (radiotherapy or radiotherapy + chemotherapy also allowed) combined with Krestin as
      second-line treatment after exacerbation, evaluate the efficacy and safety of treatment in a
      small number of cases, and compare with historical control or community control.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, Time to treatment failure (TTF), Time to progression (TTP), Progression free survival (PFS), Severity and frequency of toxicity</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan hydrochloride + Cisplatin + Krestin Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan hydrochloride</intervention_name>
    <description>Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Irinotecan hydrochloride: CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cisplatin: CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Krestin</intervention_name>
    <description>Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Krestin: PSK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically proven small cell lung cancer

          -  Patients receiving chemotherapy for the first time

          -  Patients with no indication for radical radiotherapy or surgical resection

          -  Patients diagnosed as ED* by full staging [chest X ray, chest C, brain CT or MRI,
             abdominal CT or abdominal ultrasonography, whole body bone scintigraphy (may be
             replaced by PET/CT)]

               -  ED: Patient with distant metastasis including contralateral hilar lymph node
                  metastasis, but ipsilateral pleural effusion without distant metastasis is
                  excluded.

          -  Patients with lesions measurable or evaluable by the RECIST criteria

          -  Patients aged from 20 years to below 75 years

          -  Patients with preserved organ functions as indicated by the following test values
             (data obtained within 14 days prior to registration) Hemoglobin: ≥9.0 g/dL White blood
             cell count: ≥4,000/mm3, ≤12,000 /mm3 Neutrophil count: ≥ 2,000/mm3 Platelet count:
             ≥100,000 /mm3 GOT, GPT: below 2.5 times the upper limit of normal range for individual
             facility Total bilirubin: ≤1.5 mg/dL Serum creatinine: below the lower limit of normal
             range for individual facility Creatinine clearance: ≥ 60mL/min Arterial oxygen tension
             （PaO2）: ≥60 torr (resting)

          -  Performance status (PS): 0-1

          -  Absence of serious concurrent cardiac or pulmonary disease

          -  Patients expected to survive for at least 3 months

          -  Patients from whom written informed consent can be obtained

        Exclusion Criteria:

          -  Patients with serious infection and other serious complications (including
             gastrointestinal bleeding and diarrhea)

          -  Patients with pleural effusion, ascites, or pericardial effusion that requires
             treatments including puncture drainage and intracavity administration

          -  Patients showing definite interstitial pneumonitis or pulmonary fibrosis on plain
             chest radiograph

          -  Patients manifesting central nervous system symptoms due to brain metastasis at
             registration

          -  Patients with active multiple cancers

          -  Patients who had undergone bone marrow transplantation

          -  Patients who had undergone peripheral blood stem cell transplantation

          -  Patients with a history of definite drug allergy

          -  Pregnant and nursing patients, patients who may be pregnant or who intend to become
             pregnant

          -  Male patients with reproductive capacity who have no intention of contraception during
             the clinical trial

          -  Patients with poorly controlled diabetes

          -  Patients who had been administered Krestin in the past

          -  Others: patients who are judged by the investigator or subinvestigator to be
             unsuitable as subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuhiko Kashii, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Network for Chemotherapy of Lung Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatsuhiko Kashii, MD, PhD</last_name>
    <phone>+81-76-434-7808</phone>
    <email>tkashii@med.u-toyama.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center</name>
      <address>
        <city>Sakura</city>
        <state>Chiba</state>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryoji Kato, MD</last_name>
      <phone>+81-43-462-8811</phone>
      <email>ryochan@sakura.med.toho-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Ryoji Kato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Oizumi, MD</last_name>
      <phone>+81-11-716-1161</phone>
      <email>soizumi@med.hokudai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Satoshi Oizumi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuo Kasahara, MD</last_name>
      <phone>+81-076-265-2000</phone>
      <email>kasa1237@med3.m.kanazawa-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuo Kasahara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanazawa Medical University Hospital</name>
      <address>
        <city>Uchinada</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirohisa Toga, MD</last_name>
      <phone>+81-76-286-3511</phone>
      <email>toga-h@kanazawa-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hirohisa Toga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinkidaigakuigakubu Nara Hospital</name>
      <address>
        <city>Ikoma</city>
        <state>Nara</state>
        <zip>630-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshio Shimizu, MD</last_name>
      <phone>+81-743-77-0880</phone>
      <email>tshimizu@nara.med.kindai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Toshio Shimizu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshige Yoshioka, MD</last_name>
      <phone>+81-86-422-0210</phone>
      <email>hirotin@kchnet.or.jp</email>
    </contact>
    <investigator>
      <last_name>Hirishige Yoshioka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Prefectural Medical Center for Respiratory and Allergic Diseases</name>
      <address>
        <city>Habikino</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomonori Hirasima, MD</last_name>
      <phone>+81-957-2121</phone>
      <email>hirashima@opho.jp</email>
    </contact>
    <investigator>
      <last_name>Tomonori Hirasima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinkidaigakuigakubu Sakai Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>590-0132</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minoru Takada, MD</last_name>
      <phone>+81-72-299-1120</phone>
      <email>m-takada@sakai.med.kindai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Minoru Takada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Kinki-chuo Chest Medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihito Kubo, MD</last_name>
      <phone>+81-72-252-3021</phone>
      <email>a-kubo@kch.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Akihito Kubo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Medikal College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takayasu Kurata, MD</last_name>
      <phone>+81-72-683-1221</phone>
      <email>ctc002@poh.osaka-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takayasu Kurata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasuo Iwamoto, MD</last_name>
      <phone>+81-82-221-2291</phone>
      <email>y-iwamoto@do.enjoy.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Yasuo Iwamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Takeda, MD</last_name>
      <phone>+81-6-6929-1221</phone>
      <email>kkk-take@ga2.so-net.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Koji Takeda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiro Tsuboi, MD</last_name>
      <phone>+81-3-3342-6111</phone>
      <email>mtsuboi@za2.so-net.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Masahiro Tsuboi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toyama University Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>930-0194</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuhiko Kashii, MD, PhD</last_name>
      <phone>+81-76-434-7808</phone>
      <email>tkashii@med.u-toyama.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Tatsuhiko Kashii, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toyama Red Cross Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>930-0859</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiichi Iwase, MD</last_name>
      <phone>+81-76-433-2222</phone>
      <email>iwasa@toyama-med.jrc.or.jp</email>
    </contact>
    <investigator>
      <last_name>Keiichi Iwase, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91.</citation>
    <PMID>11784874</PMID>
  </reference>
  <reference>
    <citation>Fisher MD, D'Orazio A. Irinotecan and cisplatin versus etoposide and cisplatin in small-cell lung cancer: JCOG 9511. Clin Lung Cancer. 2000 Aug;2(1):23-4.</citation>
    <PMID>14731333</PMID>
  </reference>
  <reference>
    <citation>Saijo N. Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer. 2003 Dec 15;89(12):2178-83. Review.</citation>
    <PMID>14676791</PMID>
  </reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <last_update_submitted>September 2, 2008</last_update_submitted>
  <last_update_submitted_qc>September 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tatsuhiko Kashii, MD, PhD, Associate Professor</name_title>
    <organization>Toyama University Hospital</organization>
  </responsible_party>
  <keyword>ED-SCLC</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>CPT-11</keyword>
  <keyword>irinotecan hydrochloride</keyword>
  <keyword>CDDP</keyword>
  <keyword>cisplatin</keyword>
  <keyword>PSK</keyword>
  <keyword>Krestin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

